English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Received on: 14.12.2018 Revised on: 24.02.2018 Accepted on: 27.02.2018 Cancer is a class of disease in which group of cells show out of control growth, invasions and sometimes metastasis to different parts of the body. Few side effects of cancer treatment are more feared by the patient than nausea and vomiting. Although nausea and emesis (vomiting and retching) can result from surgery or radiation therapy, chemotherapy-induced nausea and vomiting (CINV) are potentially the most severe and most distressing. A randomized, single-blind controlled clinical trial conducted in Hiwa Center for Cancer in Sulaimani city for the period from January to December 2015. A total of 70 Hodgkin lymphoma patients presented to Hiwa Center for Cancer and treated with ABVD chemotherapy regimen were selected. The patient's received either the treatment (Aprepitant, Odansitron and Dexamethasone) or the standard regimen (Odansitron, Dexamethasone) in a 1:1 ratio, computergenerated, random allocation schedule. A total of sixty-three Hodgkin lymphoma patients were included in the present study with a mean age was 47.8±14.4 years; 34.9 % of them were ageing 60 years and more. Nausea and vomiting score was significantly higher in the treatment group from 2nd day to 4th days; the number of rescue therapy was significantly higher in the standard therapy group. In conclusion, the use of Aprepitant, Odansitron and Dexamethasone regimen showed superior and valuable results in the prevention of cancer induced nausea and vomiting by patients on chemotherapy.

international journal of research in pharmaceutical sciences

Comparison of acute and delayed antiemetic effect of adding Aprepitant to Odansitron ‎and Dexamethasone regimen ‎in patients with Hodgkin lymphoma receiving highly emetogenic chemotherapy